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Abbreviations/acronyms: 
ANZRAG Australian and New Zealand Registry of Advanced Glaucoma  
BCVA  Best corrected visual acuity 
CCT  Central corneal thickness 
CDR  Cup-to-disc ratio 
IOP  Intraocular pressure 
MD  Mean deviation 
POAG  Primary Open Angle Glaucoma   
ABSTRACT 
Purpose: To assess the difference in severity of disease in Primary Open Angle Glaucoma 
(POAG) patients with a Myocilin (MYOC) disease-causing variant who presented through 
normal clinical pathways (Clinical cases) versus those who were examined following genetic 
testing (Genetic cases). 
Design: Retrospective clinical and molecular study. 
Participants: Seventy-three MYOC mutation carriers identified through the Australian and 
New Zealand Registry of Advanced Glaucoma. 
Methods: Individuals were classified based on how they first presented to an 
ophthalmologist: Clinical cases were referred by their general practitioner or optometrist, and 
Genetic cases were referred following positive results from genetic testing for the previously 
identified familial MYOC variant (cascade genetic testing). All cases were then sub-classified 
into four groups (unaffected, glaucoma suspect, glaucoma, advanced glaucoma) according to 
the severity of disease at the time of their first examination by an ophthalmologist. 
Main outcome measures: Glaucoma clinical parameters and age at presentation. 
Results: At their first examination, 83% of Genetic cases were unaffected and 17% were 
glaucoma suspect whereas among Clinical cases 44% were glaucoma suspect, 28% had 
glaucoma and 28% had advanced glaucoma. Genetic cases were significantly younger at 
presentation than Clinical cases (40.6 ± 12.5 versus 47.5 ± 16.7 years, P = 0.018). The mean 
highest intraocular pressure (17.6 ± 3.6 versus 32.2 ± 9.7 mmHg, P < 0.001), cup-to-disc 
ratio (0.48 ± 0.13 versus 0.65 ± 0.27, P = 0.006) and mean deviation on visual field testing (-
1.2 ± 1.2 versus -10.0 ± 10.3, P < 0.001) were all significantly worse in Clinical cases 
compared with Genetic cases. Individuals with MYOC common p.Gln368Ter variant were 
further analysed separately to account for the phenotypic variability of different disease-
causing variants. All findings remained significant after adjusting for the common MYOC 
p.Gln368Ter variant.  
Conclusions: Our findings demonstrated that MYOC cascade genetic testing for POAG 
allows identification of at-risk individuals at an early stage or even before signs of glaucoma 
are present. This is the first study to demonstrate the clinical utility of predictive genetic 
testing for MYOC glaucoma.  
INTRODUCTION 
Glaucoma is the leading cause of irreversible and preventable blindness worldwide.1 It refers 
to a heterogeneous set of progressive eye disorders characterized by optic disc cupping and 
corresponding visual field defects.2 Primary Open Angle Glaucoma (POAG) is the most 
common subset and affects 3% of the Australian population above the age of 50.3 Symptoms 
are usually not apparent until substantial irreversible damage has occurred. Therefore we need 
to facilitate early diagnosis in order to prevent vision loss.  Approximately half of those affected 
remain undiagnosed,3,4 suggesting that current screening strategies lack efficacy. 
POAG has a strong genetic component.5 Individuals with an affected first-degree relative are 
9 times more likely to develop glaucoma compared with the general population.6 The Myocilin 
(MYOC) gene was the first gene associated with POAG.7,8 MYOC disease-causing variants 
have been identified in 2-4% of unselected POAG patients and in 8-36% of POAG patients 
diagnosed before 40 years of age.9-11 The variants are inherited in an autosomal dominant 
fashion with high penetrance, and carriers usually demonstrate elevated intraocular pressure 
(IOP) with an earlier age of onset than POAG patients without MYOC variants.10 There is an 
enrichment of MYOC variants in patients with advanced POAG, indicating a progression to a 
more severe disease, particularly without treatment.10 Since the discovery of the MYOC gene 
in 1997, over 80 disease-causing variants have been described, with the p.Gln368Ter variant 
the most common.12 Although clear genotype-phenotype correlations exist, inter- and intra-
familial phenotypic variability is also well acknowledged. The p.Gln368Ter variant has a 
variable age-related penetrance with 50% of carriers diagnosed with glaucoma by 50 years of 
age.13 Other disease-causing variants such as p.Pro370Leu or p.Gly367Arg are more severe 
and are associated with complete penetrance by 50 years of age.9,10,14,15 The exact mechanism 
of MYOC variants leading to disease has not yet been fully elucidated. There is evidence to 
suggest that the abnormal gene protein products accumulate in the trabecular meshwork 
contributing to outflow obstruction and ultimately increasing IOP.16,17 
POAG is treated by lowering IOP; it is an effective strategy to slow progression or to prevent 
disease development, provided patients are identified early in the disease process.18,19 Lowering 
IOP is achieved with medical therapy, with laser or with incisional surgical interventions. In 
the era of personalized medicine, the ability to predict disease development can allow tailored, 
specific treatment plans for individuals. Considering the difficulties in diagnosing glaucoma 
early, the younger age of onset for MYOC carriers compared with the general population and 
the availability of effective preventive measures for treating POAG, genetic testing of relatives 
for the previously identified familial MYOC variant (cascade genetic testing) offers the 
potential to improve patient care and to prevent glaucoma blindness.20,21 No previous study has 
examined the possible clinical benefits of MYOC cascade genetic testing. 
Established in 2007, the Australian and New Zealand Registry of Advanced Glaucoma 
(ANZRAG) has gathered the largest cohort of patients with advanced glaucoma with the aim 
to identify genetic risk factors for glaucoma blindness.22 The ANZRAG offers all participants 
with MYOC disease-causing variants the opportunity to have cascade genetic testing performed 
on all first-degree family members over the age of 18. Using the ANZRAG, this study aimed 
to assess the clinical utility of performing cascade genetic testing by comparing the disease 
severity of POAG patients with a MYOC disease-causing variant who presented through usual 
clinical care pathways with those who were examined following genetic testing. 
 
METHODS 
Ethics Committee approval was obtained through the Southern Adelaide and Flinders 
University Clinical Research Ethics Committee. The study adhered to the tenets of the 
Declaration of Helsinki and followed the National Health and Medical Research Council 
statement of ethical conduct in research involving humans. Informed consent was obtained 
from all participants. 
Participant recruitment into the ANZRAG has been described previously.22 Patients with all 
levels of glaucoma could be referred to the ANZRAG by clinicians. Advanced glaucoma was 
defined as central visual field loss related to glaucoma with at least 2 of the 4 central fixation 
squares having a pattern standard deviation probability of less than 0.5% on a reliable 
Humphrey 24-2 field, or a mean deviation (MD) of less than -22 dB, or in the absence of visual 
field testing, best-corrected visual acuity (BCVA) worse than 20/200 due to glaucoma. 
Participants also needed evidence of glaucoma in the less severely affected eye characterized 
by glaucomatous visual field defects with corresponding optic disc rim thinning. Non-advanced 
glaucoma was defined by glaucomatous visual field defects, with corresponding optic disc rim 
thinning, including an enlarged cup-to-disc ratio (CDR) (≥0.7) or CDR asymmetry (≥0.2) 
between both eyes. Glaucoma suspects had ocular hypertension as defined by IOP >21 mmHg 
or had pre-perimetric glaucoma with no glaucomatous field changes. 
Advanced and non-advanced POAG cases recruited in the ANZRAG were screened for MYOC 
as previously described.10 Glaucoma suspects who did not meet the advanced or non-advanced 
criteria but had a combination of ocular hypertension, young age and positive family history of 
glaucoma were also screened. Through the proband, cascade genetic testing and counselling 
were offered to first-degree family members over the age of 18 who were either affected or 
unaffected. 
This study retrospectively identified the manner in which patients with an underlying MYOC 
disease-causing variant first presented to an ophthalmologist and aimed to capture a clinical 
picture of the patient at the time of their first presentation. All participants with MYOC variants 
were categorized into two main groups: participants who were referred to an ophthalmologist 
for the first time by their general practitioner or optometrist (Clinical group) and those who 
were referred to an ophthalmologist for the first time following genetic testing results (Genetic 
group). Participants’ clinical parameters recorded at the time of their first presentation to an 
ophthalmologist were collected. The data collected included demographic information, IOP, 
CDR, central corneal thickness (CCT), BCVA, and reliable visual field testing parameters 
including MD. Once cases were classified according to their mode of presentation, they were 
further sub-classified into four groups according to the severity of disease at the time of their 
first presentation: normal, glaucoma suspect, non-advanced glaucoma, and advanced 
glaucoma, as described above. 
Data were analysed for all participants with MYOC disease-causing variants identified in the 
ANZRAG that satisfied inclusion criterion. BCVA was transformed in decimal fractions for 
analysis purposes. Due to the phenotypic variations of underlying MYOC variants, additional 
analysis was also performed on participants carrying p.Gln368Ter only, as it is the most 
common disease-causing variant. Clinical data were analysed with PASW Statistics, Rel. 
18.0.1.2009. Chicago: SPSS Inc. Data are presented as mean ± standard deviation. The Mann-
Whitney-U test was used for the assessment of differences in nonparametric data and Chi 
square tests for categorical data. 
 
RESULTS 
Ninety-seven participants with a MYOC disease-causing variant were identified in the 
ANZRAG. Of these, clinical details at presentation could be obtained for 73 (75%) participants 
included in the study. They consisted of 43 (59%) Clinical cases and 30 (41%) Genetic cases. 
There were 39 (53%) female and 34 (47%) male patients. The mean current age was 60.9 ± 
17.7 years (range 16-87 years) for Clinical cases and 44.7 ± 11.9 years (range 24-77 years) for 
Genetic cases. Genetic cases were significantly younger at presentation than Clinical cases 
(40.6 ± 12.5 versus 47.5 ± 16.7 years, P = 0.018). At their first examination, 25 (83%) Genetic 
cases were unaffected and 5 (17%) were glaucoma suspect whereas among Clinical cases 19 
(44%) were glaucoma suspect, 12 (28%) had non-advanced glaucoma and 12 (28%) had 
advanced glaucoma (Figure 1). Among the Genetic cases, unaffected individuals were 
significantly younger compared to glaucoma suspects (42.5 ± 10.4 versus 55.8 ± 13.7 years, P 
= 0.037). 
The mean highest IOP (17.6 ± 3.6 versus 32.2 ± 9.7 mmHg, P < 0.001), highest CDR (0.48 ± 
0.13 versus 0.65 ± 0.27, P = 0.006), worst MD (-1.2 ± 1.2 versus -10.0 ± 10.3, P < 0.001), and 
worst BCVA (0.96 ± 0.30 versus 0.70 ± 0.38, P = 0.004) were all significantly less severe 
among Genetic cases compared with Clinical cases (Figure 2). The mean CCT was similar 
between the groups (561.3 ± 37.2 versus 538.7 ± 42.6, P = 0.52). Elevated IOP at presentation 
was recorded for 91% (39/43) of Clinical cases versus 10% (3/30) of Genetic cases. We 
conducted the same analyses including only one relative per family to account for the 
characteristics that individuals from the same family may share and obtained similar results 
(not shown). 
Probands and siblings 
We then analyzed separately the probands and their siblings, including 38 Clinical and 9 
Genetic cases. The mean age at presentation was similar in both groups (48.29 ± 17.0 years 
Clinical versus 45.3 ± 15.2 years Genetic, P = 0.401). At presentation 16 were glaucoma 
suspect, 11 had non-advanced glaucoma and 11 had advanced glaucoma among Clinical cases, 
whereas 5 were unaffected and 4 were glaucoma suspect among Genetic cases. 
The mean highest IOP (20.2 ± 3.2 versus 32.2 ± 10.0 mmHg, P < 0.001), highest CDR (0.46 ± 
0.18 versus 0.66 ± 0.27, P = 0.026) and worst MD (-1.3 ± 1.1 versus -10.9 ± 10.4, P = 0.017) 
were all significantly less severe among Genetic cases compared with Clinical cases. Although 
not significant, the worst BCVA was also less severe in Genetic cases compared with Clinical 
cases (0.91 ± 0.27 versus 0.70 ± 0.39, P = 0.128). The mean CCT was significantly different 
between both groups (569.7 ± 29.6 Genetic versus 536.0 ± 42.8 Clinical). Elevated IOP was 
reported for 92% (35/38) of Clinical cases versus 22% of Genetic cases. 
Probands and offsprings 
Next, we analyzed probands and their offsprings, comprising 35 Clinical and 21 Genetic cases. 
The mean age at presentation was significantly lower among Genetic (41.7 ± 9.4 years) 
compared with Clinical cases (62.1 ± 17.1, P = 0.002). Among the Clinical cases, 14 were 
glaucoma suspect, 11 had glaucoma and 11 had advanced glaucoma at presentation whereas 
20 Genetic cases were unaffected and 1 was a glaucoma suspect. 
The mean highest IOP (16.5 ± 3.1 versus 32.2 ± 9.8 mmHg, P < 0.001), highest CDR (0.49 ± 
0.11 versus 0.67 ± 0.26, P = 0.004), worst MD (-1.0 ± 1.0 versus -10.3 ± 10.0, P < 0.001) and 
worst BCVA (1.01 ± 0.31 versus 0.71 ± 0.38, P = 0.003) were all significantly less severe in 
Genetic cases compared with Clinical cases. The mean CCT was similar between both groups 
(553.5 ± 42.0 versus 533.5 ± 44.4, P = 0.204). Elevated IOP was recorded in 89% (31/35) of 
the Clinical cases compared with 5% (1/21) of the Genetic cases.  
Carriers of MYOC p.Gln368Ter 
Individuals with the p.Gln368Ter variant totaled 52 cases, 71% of the total study population. 
Of the 52 p.Gln368Ter cases, 28 (54%) were Clinical cases and 24 (46%) were Genetic cases. 
The mean current age was 68.4 ± 8.8 years (range 53-87 years) for Clinical cases and 44.7 ± 
12.7 years (range 24-77 years) for Genetic cases. The mean age at presentation was 
significantly younger among Genetic cases compared with Clinical cases (40.5 ± 13.3 versus 
55.0 ± 9.8 years, P < 0.001). Among Genetic cases, 19 were unaffected and 5 were glaucoma 
suspect at presentation whereas 12 Clinical cases were glaucoma suspect, 8 had non-advanced 
glaucoma and 8 had advanced glaucoma. 
The mean highest IOP (18.0 ± 3.7 versus 29.9 ± 9.3 mmHg, P < 0.001), highest CDR (0.49 ± 
0.14 versus 0.66 ± 0.27, P = 0.016), worst MD (-1.3 ± 1.2 versus -9.2 ± 10.0, P = 0.010), and 
worst BCVA (0.95 ± 0.29 versus 0.67 ± 0.41, P = 0.009) were all significantly less severe 
among Genetic cases compared with Clinical cases with p.Gln368Ter (Figure 3). The mean 
CCT was significantly higher among Genetic cases compared with Clinical cases (569.4 ± 32.5 
versus 530.1 ± 40.8, P = 0.004). Increased IOP at presentation was recorded for 86% (24/28) 
of Clinical cases versus 13% (3/24) of Genetic cases. Figure 4 shows higher IOP and lower 
MD with a later age at presentation for Clinical cases compared with Genetic cases. 
Response to treatment 
The IOP before and after treatment was available for 83% (35/42) of the glaucoma suspects 
and affected individuals included in the study who were on treatment. All individuals attained 
IOP within the normal range with IOP-lowering therapy. The mean highest IOP before 
treatment was 31.8 ± 1.4 mmHg (range 21-52 mmHg) versus 16.8 ± 0.4 mmHg (range 12-21 
mmHg) after initiation of treatment (P < 0.001). 
 
DISCUSSION 
Glaucoma can lead to irreversible blindness if left untreated and often remains undiagnosed 
until substantial damage has occurred. It is crucial to identify at-risk individuals at the earliest 
opportunity because there are medical and surgical treatment options that are effective for 
slowing down the progression of or even preventing glaucoma from developing.18,19 MYOC 
disease-causing variants exhibit a strong age-dependent penetrance and affected individuals 
present with more advanced disease if not identified and treated early.10 Despite evidence 
supporting clinical validity and patient’s acceptance for MYOC genetic testing,20,21 there is a 
lack of outcome measures and evidence-based clinical utility for genetic testing for the 
monogenic forms of glaucoma. This study is the first to investigate the clinical utility of 
cascade genetic testing for MYOC by examining the clinical parameters at time of presentation 
of MYOC carriers. 
We showed that patients identified via cascade genetic testing presented 7 years younger than 
those identified following ophthalmic referral. The majority (83%) of carriers identified 
through genetic testing were asymptomatic at the time of presentation whereas half of the 
patients who had an ophthalmic referral had early signs of glaucoma and the other half already 
had glaucoma, including 28% with advanced disease. All clinical parameters related to 
glaucoma (IOP, CDR and MD on visual field test) were significantly worse at presentation 
among Clinical cases compared with Genetic ones. 
We conducted separate analyses on probands/siblings and probands/offsprings to evaluate 
whether the age difference affected our findings. As expected, the age at presentation was 
significantly younger in Genetic cases compared with Clinical cases within the 
probands/children group whereas the age at presentation was similar between Clinical and 
Genetic cases within the probands/siblings group. There were fewer siblings than offsprings in 
the Genetic group, which can be explained by a proportion of siblings already affected by 
glaucoma and not identified through genetic testing. In both analyses, the clinical parameters 
associated with glaucoma were significantly less severe in Genetic cases compared with 
Clinical cases. Forty-four percent of the siblings were identified as glaucoma suspect following 
genetic testing results. However the siblings in the Genetic group had better glaucoma 
parameters than the probands, despite the fact that they presented at a similar age than the 
probands and that almost half of them had early signs of glaucoma. These findings highlight 
the usefulness of cascade genetic testing irrespective of the age of the family members. 
Genotype-phenotype correlations have been well described for MYOC variants.10-12 In order to 
reduce the variability accounted for by disease-causing variants of different severity, we 
analysed individuals carrying only the most common MYOC variant (p.Gln368Ter) separately. 
p.Gln368Ter is usually associated with a moderate severity and displays an age-related 
penetrance with half of the carriers being diagnosed with glaucoma by 50 years of age and 
almost all carriers diagnosed by 75 years of age.13 When considering p.Gln368Ter carriers 
only, individuals diagnosed early because of more severe MYOC variants are excluded as 
shown by the older age at presentation among p.Gln368Ter carriers. Our results showed that 
p.Gln368Ter carriers identified through genetic testing presented 15 years younger than those 
who presented clinically. They also show better clinical parameters at presentation as illustrated 
by lower IOPs, CDR and MD on visual field test than their clinically diagnosed counterparts. 
Glaucoma suspects identified by ophthalmic presentation were on average in their early 50s, 
which is in accordance with the age-related penetrance for this variant. Unaffected individuals 
identified through genetic testing were on average in their late 30s (37.1 ± 2.5 years), an age 
group where a minority of p.Gln368Ter carriers are affected. This shows the ability of cascade 
genetic testing to identify gene carriers before they exhibit symptoms of the disease. 
Among the individuals carrying variants other than p.Gln368Ter, some had a more severe 
disease with an early age of glaucoma onset. In these families, we would expect cascade genetic 
testing to have similar positive outcomes if conducted at an early age, and we have previously 
discussed the benefits of a genetic testing approach for minors in these families.23 Our numbers 
were too small to analyze this group separately in this study but future studies should examine 
the clinical utility of genetic testing in individuals carrying MYOC variants associated with 
early glaucoma onset. Similarly, our findings could be extrapolated to other monogenic rarer 
forms of the disease such as Optineurin and TBK1 glaucoma associated variants. However the 
utility of a genetic testing approach is currently less clear in the complex and more common 
forms of glaucoma that are the result of multiple genetic factors with small effect size. 
Through our cascade testing program, we make genetic testing available to all first-degree 
relatives but we do not contact relatives directly to promote autonomous and noncoercive 
decisions. This approach yields a response rate of 50% which is similar to other adult-onset 
conditions with treatment options and high penetrance genes such as inherited cancers and 
cardiomyopathies.24,25 Individuals with a family history are more likely to access screening for 
glaucoma.26 However, in our cohort 79% (33/42) of individuals who presented clinically had a 
family history, including 67% (16/24) who presented with glaucoma. This suggests that family 
history may not be enough of a risk factor to diagnose at-risk individuals early. Additionally, 
we previously showed that the majority of newly identified MYOC carriers had never seen an 
eye specialist,10 supporting genetic testing as an effective way to identify at-risk individuals in 
MYOC families in a more timely manner. 
In this study, 25 individuals had no signs of glaucoma on examination following genetic results. 
These individuals were significantly younger than those identified as glaucoma suspects 
following genetic results. MYOC variants are highly penetrant: Age-related penetrance is 
complete at 50 years old for MYOC variants associated with an early age of onset9,10,14,15 and 
almost complete at 75 years old for the common p.Gln368Ter variant.13 Therefore, these 
unaffected individuals are expected to develop glaucoma at some stage. Interestingly, we are 
aware of two individual who subsequently converted to glaucoma suspect in the Genetic group 
on follow-up. Long-term studies that follow at-risk asymptomatic individuals are still needed 
to assess clinical outcomes, the progression of the disease and the best treatment strategies for 
MYOC carriers. 
Cascade genetic screening for glaucoma is a promising avenue to prevent glaucoma blindness.  
A previous study demonstrated the acceptability of predictive genetic testing for MYOC 
glaucoma.20 Data from the ANZRAG have recently shown that families perceived strong 
benefits to cascade testing as it leads to the possibility of preventive measures.21 We have 
previously shown that MYOC disease-causing variants are more prevalent in the advanced 
stages of glaucoma.10 As a result early diagnosis is important as carriers may require earlier 
interventions and more aggressive management of their IOP. Our findings also confirm that 
MYOC carriers respond to IOP-lowering therapy. Personalized medicine using genetic 
information to predict disease development and to tailor preventative interventions for each 
patient is an evolving field.27 Although current glaucoma therapies are effective in lowering 
IOP in patients with MYOC disease-causing variants, targeted therapies for MYOC glaucoma 
are emerging; studies have shown a reduction in the glaucomatous phenotype of MYOC-
transgenic mice treated with topical ocular sodium 4-phenylbutyrate28 and MYOC-transgenic 
mice with CRISPR-Cas9 mediated genome editing (Jain A, Zode G, Buge K, et al. CRISPR-
Cas9 mediated genome editing of Myocilin in hereditary glaucoma. Presented at ASHG Annual 
Meeting, October 7, 2015; Baltimore). The identification of MYOC carriers will become even 
more important with the development of therapies targeted for MYOC glaucoma. 
This study has some potential limitations. First, there might be a recruitment bias as patients 
who are more likely to have undiagnosed glaucoma are also the ones who will not seek genetic 
testing and are less likely to be screened.21 The ANZRAG recruits individuals with both 
advanced and non-advanced POAG but has a recruitment bias toward more advanced disease, 
which could have resulted in an overestimation of the severity in the Clinical group. Second, 
this is a retrospective study and clinical details at the time of initial diagnosis were missing for 
25% of participants with a MYOC variant. Many of them had been diagnosed decades ago, and 
as such, records of the initial presenting details no longer existed or were irretrievable. 
However, a randomized clinical trial to study the efficacy of genetic testing for glaucoma 
leading to better visual outcome would be impossible to conduct. So although a retrospective 
study collecting clinical evidence has limitations, this is the first study to report such findings.  
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Figure legends: 
Figure 1: Diagram of the study showing the number of participants in the Clinical and Genetic 
groups and their glaucoma status at first presentation. Clinical cases were referred by their 
general practitioner or optometrist, and Genetic cases were referred following genetic test 
results. 
 
Figure 2: Comparison of the clinical characteristics between Clinical and Genetic cases with 
a MYOC variant. IOP: Intraocular pressure, CDR: cup-to-disc ratio, MD: mean deviation 
from a reliable visual field test. ** P ≤ 0.01, *** P ≤ 0.001 
 
Figure 3: Comparison of the clinical characteristics between Clinical and Genetic cases with 
the p.Gln368Ter MYOC variant. IOP: Intraocular pressure, CDR: cup-to-disc ratio, MD: mean 
deviation from a reliable visual field test. * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001 
 
Figure 4: Clinical details in relation to the age at presentation between Clinical and Genetic 
cases with the p.Gln368Ter MYOC variant. IOP: Intraocular pressure, MD: mean deviation 
from a reliable visual field test. 
